Guillain-Barré Syndrome
Guillain-Barré syndrome (GBS) is an acute, immune-mediated polyradiculoneuropathy and one of the most common neuromuscular emergencies worldwide. GBS encompasses multiple clinical variants and divergent pathogenic mechanisms that produce axonal, demyelinating, or mixed findings on electrodiagnostic studies. Despite available immunotherapies, at least 20% of patients have a poor prognosis with significant residual deficits, and mortality reaches 20% in ventilator-dependent patients.
Bottom Line
- Incidence: 0.81–1.91 per 100,000 person-years; demyelinating forms dominate in the West, axonal subtypes in Asia; men affected more commonly than women
- Clinical hallmark: A four-phase course (prodromal → progressive → plateau → recovery) with progression not exceeding 4 weeks; symmetric ascending weakness with areflexia is the classic presentation
- Variants: AIDP (~85–90% in Western countries), AMAN, AMSAN, Miller Fisher syndrome (ophthalmoplegia, ataxia, areflexia with anti-GQ1b antibodies), and several localized forms
- Pathogenesis: Molecular mimicry between pathogen antigens and neural gangliosides drives complement-mediated nerve injury; Campylobacter jejuni is the most common antecedent infection (30% of cases)
- Diagnosis: Clinical criteria (progressive weakness + areflexia), CSF albuminocytologic dissociation, and electrodiagnostic studies; MRI nerve root enhancement is supportive
- Treatment: IVIg and plasma exchange are equally effective; corticosteroids are NOT beneficial; supportive ICU care is critical for the 10–30% requiring mechanical ventilation
- Prognosis: ~80% walk independently at 1 year; validated tools (EGRIS, mEGOS) predict respiratory failure risk and functional outcome; serum neurofilament light chain is an emerging prognostic biomarker
Epidemiology
GBS is a rare, global disease with an incidence of 0.81 to 1.91 cases per 100,000 person-years in Europe and North America. Significant regional differences exist in the distribution of disease subtypes: demyelinating forms with a respiratory prodrome dominate in Europe and North America, whereas axonal subtypes preceded by diarrheal illness are more common in Asia, particularly in Bangladesh and northern China. Unlike most autoimmune diseases, GBS more commonly affects men than women, and incidence increases with advancing age.
Antecedent Infections
Infections are the most common antecedent event, occurring a median of approximately 10 days before symptom onset. Analysis of the first 1,000 patients in the International GBS Outcome Study (IGOS) provided several key observations:
- Campylobacter jejuni: The most common preceding infection overall (30% of all cases), associated with the most severe GBS presentations across all geographic regions
- Cytomegalovirus: Associated with a higher percentage of demyelinating electrophysiologic features
- Mycoplasma pneumoniae: The most common preceding infection in children
- Hepatitis E virus and Epstein-Barr virus: Consistently associated with GBS in case-control studies
- Regional differences: Zika virus outbreaks in French Polynesia, Latin America, and the Caribbean; dengue and chikungunya virus in tropical countries (e.g., south India)
- Subclinical infections: Found in 28% of patients with GBS; coinfections documented in 6%
Host immunogenetic factors, such as variations in ganglioside distribution or antibody binding ability, and microbial factors, such as differences in C. jejuni strains (Japan strain O-19 versus South Africa strain O-41) and genetic polymorphisms in lipopolysaccharide biosynthesis genes, influence the development of specific GBS subtypes.
Vaccine Associations
The relationship between GBS and vaccination first came to light during the 1976 H1N1 epidemic. Key evidence regarding COVID-19 vaccines:
- Ad.26.COV2.S (Janssen) vaccine: GBS incidence of 32.4 per 100,000 person-years in the 21 days post-vaccination — substantially greater than the background rate of 1–2 per 100,000
- mRNA vaccines (Pfizer-BioNTech, Moderna): GBS incidence of 1.3 per 100,000 person-years — similar to the expected background rate, providing evidence that mRNA vaccines are not associated with GBS
- A causal relationship between COVID-19 vaccination and GBS has not been established at a magnitude that outweighs vaccination benefits
Vaccination After GBS
- Routine vaccinations after GBS are advised due to the low risk of GBS triggered by vaccine administration (1–2 additional cases per million vaccinated), which is significantly lower than the risk posed by infection
- Immunization is avoided during the acute phase and may be postponed for a few months due to the possibility that immunotherapies may impair the immunologic response
- Future avoidance of a particular vaccine may be considered when GBS manifests within 6 weeks of receiving that vaccination
- For patients with a history of GBS, mRNA COVID-19 vaccines can be considered given the potential increased risk linked with Ad26.COV2.S
Clinical Course
A distinctive four-phase clinical course is the key hallmark of all GBS subtypes:
| Phase | Duration | Characteristics |
|---|---|---|
| Prodromal | 1–4 weeks before onset | Antecedent event (infectious or noninfectious) triggers breakdown of immune tolerance |
| Progressive | Up to 4 weeks (typically nadir by 2 weeks) | Development of neuropathy symptoms; by definition should not progress beyond 4 weeks; can progress alarmingly fast with respiratory failure within 12–24 hours |
| Plateau | 1–4 weeks (median 1 week) | Stable deficits at maximum severity |
| Recovery | Weeks to months | Gradual improvement; >95% experience a monophasic course; <5% have documented recurrence |
Treatment-Related Fluctuations vs. Acute-Onset CIDP
Treatment-related fluctuations — defined as up to two relapses with worsening of at least one grade on the GBS disability scale within 8 weeks of treatment initiation — occur in up to 10% of cases and often respond to retreatment with the previously administered immunotherapy. Rapid pharmacokinetic clearance of IVIg leading to a shortened half-life is a potential explanation. However, in patients with three or more relapses or progression beyond 8 weeks, the diagnosis of acute-onset chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) should be considered.
Distinguishing Acute-Onset CIDP from GBS
- Patients with acute-onset CIDP are more likely to have sensory deficits or ataxia
- They are less likely to have had a preceding infectious illness, autonomic involvement, facial weakness, or need for mechanical ventilation
- Electrophysiologic findings are similar between AIDP and acute-onset CIDP
- Acute-onset CIDP requires long-term immunosuppressive treatment rather than a single course of immunotherapy
- A subacute form (nadir 4–8 weeks) exists as an intermediate between GBS and CIDP and requires careful follow-up
Clinical Features
Motor Involvement
Since GBS is primarily a motor more than a sensory neuropathy, the main characteristic is symmetric weakness involving proximal and distal muscles. The involvement of both proximal nerve roots and distal nerves (hence polyradiculoneuropathy) explains the weakness pattern, particularly at areas where the blood-nerve barrier is weak. An ascending pattern (legs earlier and weaker than arms) is more common than a descending presentation.
Reflexes
Hyporeflexia or areflexia is present in approximately 90% of patients; however, this may be delayed by up to a week. Some patients with AMAN or Bickerstaff variants may have preserved reflexes or even hyperreflexia.
Sensory Features
The earliest symptoms are distal paresthesia (acroparesthesia) and low back pain (from nerve root inflammation), reported by approximately two-thirds of patients. The presence of sensory symptoms helps exclude pure motor disorders such as motor neuron disease, myopathy, or myasthenia gravis; however, objective sensory loss is mild and delayed.
Cranial Nerve Involvement
- Facial weakness: 50% of patients
- Oropharyngeal dysfunction: 40% of patients
- Ophthalmoplegia or ptosis: 5–15% of patients
- Respiratory muscle weakness: 10–30% require ventilatory support, particularly from diaphragmatic involvement
Autonomic Dysfunction
About two-thirds of patients have one or more autonomic abnormalities. Sympathetic hyperactivity typically predominates in the acute phase, and parasympathetic failure is more prominent in the recovery phase.
Autonomic Manifestations in GBS
- Cardiac: Sustained sinus tachycardia (most common), other arrhythmias
- Blood pressure: Labile hypertension (rarely causing PRES or takotsubo cardiomyopathy from catecholamine excess); orthostatic hypotension from disrupted baroreceptor reflexes
- Sweating abnormalities and pupillary dysfunction
- GI/GU: Paralytic ileus, urinary retention — may mimic spinal cord lesion with double incontinence and a pseudosensory level in 5% of cases
- Management caveat: Antihypertensive and antiarrhythmic medications should be prescribed very cautiously, especially in older adults, as they can cause severe hypotension or aggravate arrhythmias
Uncommon features include papilledema (associated with severely elevated CSF protein), facial myokymia, hearing loss, meningeal signs, and vocal cord paralysis.
GBS Variants
Axonal Variants
| Feature | AMAN | AMSAN |
|---|---|---|
| Geography | More prevalent in Asia | Less geographic/seasonal pattern |
| Antecedent event | Typically preceded by diarrhea (C. jejuni) | Characteristically preceded by respiratory illness |
| Age | More common in children, summertime | More common in adults |
| Severity | Variable (see recovery patterns below) | Often clinically more severe, with frequent autonomic and cranial nerve dysfunction |
| Reflexes | May be normal or even exaggerated | Typically reduced or absent |
| Sensory involvement | Absent (pure motor) | Present (motor and sensory) |
| Recovery | Two patterns: rapid (reversible conduction failure) or slow/poor (axonal degeneration) | Early nadir, protracted course, severe residual disability |
Miller Fisher Syndrome
Miller Fisher syndrome (MFS) includes a spectrum of disorders with serum anti-GQ1b antibodies in approximately 85–90% of patients. The complete form is characterized by the classic triad of ophthalmoplegia, ataxia, and areflexia and is more common in East Asia, particularly Japan. Ataxia arises from either cerebellar pathology (central) or selective involvement of Ia afferent neurons (peripheral).
- Incomplete forms: Acute ophthalmoplegia, acute ataxic neuropathy, acute ptosis, mydriasis, and acute vestibular syndromes
- Bickerstaff brainstem encephalitis: An MFS-related disorder with impaired consciousness and paradoxical hyperreflexia (from reticular formation and pyramidal tract involvement), in addition to ataxia and ophthalmoparesis; brain MRI abnormalities in only 30% of cases
- MFS-GBS overlap: Patients with MFS features who develop limb weakness and respiratory insufficiency
Localized Variants
- Pharyngeal-cervical-brachial: Weakness of oropharynx, neck, and shoulders sparing the lower limbs — mimics botulism
- Paraparetic: Lower limb weakness only — mimics acute spinal cord lesion
- Bilateral facial palsy with paresthesia
- Acute bulbar palsy
- Pure sensory ataxic variant
- Acute pandysautonomia: Isolated autonomic nerve involvement
Pathogenesis
Molecular Mimicry
Similarities between pathogen antigenic structures and human neural gangliosides (molecular mimicry) drive humoral and T-cell-mediated immune responses following infections such as C. jejuni. The immune cascade involves: antigen-presenting cell recognition of ganglioside-like lipooligosaccharides → autoreactive T-cell proliferation → cytokine-mediated blood-nerve barrier breakdown → antimyelin antibody production → complement activation and membrane attack complex formation → demyelination and/or axonal loss → macrophage invasion to clear debris.
Ganglioside Targets
| GBS Subtype | Target Antigens |
|---|---|
| AIDP | LM1, Gal-C |
| AMAN | GM1, GM2, GD1b, GT1b, GM3, GD1a, GalNAc-GD1a |
| AMSAN | GM1, GM1b, GD1a |
| Miller Fisher syndrome | GQ1b, GM1b, GT1a, GD3, GD1c |
| Bickerstaff brainstem encephalitis | GQ1b |
| Pharyngeal-cervical-brachial | GT1a, GQ1b, GD1b |
| Sensory ataxic variant | GD1b |
The localization of target gangliosides and the binding specificity of antiglycolipid antibodies account for distinctive clinical subtypes. GM1 and GD1a, highly expressed on motor neuron axolemma at the node of Ranvier, are associated with motor abnormalities. GQ1b, strongly expressed in extraocular muscles, muscle spindles, and reticular formation, accounts for ophthalmoplegia, ataxia, and altered consciousness. GT1a expression in glossopharyngeal and vagal nerves explains dysphagia.
AIDP Pathology
In AIDP, autoantibodies bind to myelin antigens, activate complement to form MAC on Schwann cell surfaces, and initiate vesicular degeneration of myelin. Demyelination and multifocal perivascular and endoneurial T-cell infiltration occur along the nerve length, particularly at the proximal nerve roots and distal nerve segments where the blood-nerve barrier is weakest. After myelin clearance, Schwann cells produce offspring that create short internodes within the existing internode — these are responsible for persistent conduction abnormalities on electrodiagnostic studies, even after good clinical recovery.
AMAN Pathology (Nodopathy)
In AMAN, IgG anti-GM1 or anti-GD1a autoantibodies bind to the nodal axolemma at the nodes of Ranvier, leading to complement activation and MAC formation. This causes disappearance of nodal sodium channels and disruption of axoglial junctions, resulting in nerve conduction block. These changes can be reversible (reversible conduction failure) with treatment, producing rapid recovery. However, intense immunologic activation may trigger intra-axonal calcium accumulation through sodium/potassium pump inhibition and MAC pore formation, leading to irreversible axonal degeneration and poor outcomes.
Diagnostic Criteria
| Diagnostic Criteria for GBS (Asbury & Cornblath) | |
|---|---|
| Features required for diagnosis | Progressive weakness of more than one limb; areflexia or hyporeflexia |
| Strongly supportive features | Progression over days to 4 weeks; relative symmetry; mild sensory symptoms/signs; cranial nerve involvement (especially bilateral facial weakness); autonomic dysfunction; pain; elevated CSF protein; characteristic electrodiagnostic features |
Red Flags Suggesting Alternative Diagnosis
- Severe respiratory dysfunction with limited limb weakness at onset
- Slow progression over 4 weeks without cranial nerve, autonomic, or respiratory involvement
- Severe sensory signs with limited weakness at onset
- Bladder or bowel dysfunction at onset
- Sharp sensory level on torso
- Marked persistent asymmetric weakness
- Fever at onset
- CSF pleocytosis (>50 × 106/L), particularly if polymorphonuclear cells are prominent
Investigations
Laboratory Studies
All patients should undergo initial screening to exclude other causes of acute weakness: complete blood count, comprehensive metabolic profile, glycosylated hemoglobin, and thyroid function testing. Testing for antecedent infections may offer prognostic information but does not change management. With the notable exception of anti-GQ1b antibodies (found in up to 90% of patients with MFS), the diagnostic value of other antiganglioside antibodies is limited and assay-dependent, and routine testing is not recommended.
CSF Analysis
Elevated total protein with normal cell count (albuminocytologic dissociation) is the hallmark CSF abnormality, explained by increased blood-nerve barrier permeability at the proximal nerve roots. Key points:
- CSF protein may be normal in the first week (up to 50% of patients) but is elevated in >90% by the end of week 2
- High CSF protein is linked to demyelinating subtype and severe short-term disease course
- Mild pleocytosis (10–20 cells/mm³) is seen in up to 5% of cases
- Marked pleocytosis (>50 cells/mm³) should prompt evaluation for alternative causes (HIV, Lyme disease, leptomeningeal disease)
- IVIg therapy can raise CSF protein and white blood cell counts, complicating interpretation after treatment initiation
Electrodiagnostic Studies
Nerve conduction studies and needle EMG are critical for confirming the diagnosis, excluding mimics, differentiating axonal from demyelinating subtypes, and estimating the extent of axonal loss. Patients may require two studies 1–3 weeks apart, as initial studies may be normal or nonspecific when performed early.
Key Electrodiagnostic Findings by Subtype
- Demyelinating (AIDP): Prolonged or absent F waves and H reflexes; increased distal latency and conduction block with temporal dispersion; prolonged distal CMAP duration >8.5 ms (65% sensitivity, 98% specificity); reduced motor conduction velocities (not until week 3–4, reflecting remyelination with short internodes); sural sparing pattern (16% sensitivity, 98% specificity)
- Axonal (AMAN): Stable or worsening distal CMAP amplitudes with preserved sensory amplitudes, distal latencies, and conduction velocities; absent temporal dispersion; OR rapidly resolving low-amplitude CMAPs indicating reversible conduction failure (associated with prompt recovery)
- AMSAN: Both CMAP and SNAP amplitudes reduced; reversible conduction failure may occur in both motor and sensory nerves
- Caution: If distal reversible conduction failure is not recognized in AMAN, an incorrect diagnosis of axonal degeneration may be made, leading to an incorrect poor prognosis
Neuroimaging
MRI is not part of the routine diagnostic evaluation but can be valuable in specific situations:
- Spinal MRI: Thickening or enhancement of intrathecal spinal nerve roots and cauda equina with 83% sensitivity — particularly useful in young children where clinical and electrophysiologic examinations can be difficult
- Cranial nerve enhancement: Described in Miller Fisher syndrome cases, along with posterior column enhancement
- Utility: Helpful in the presence of red flags, for identifying certain variants (MFS, pharyngeal-cervical-brachial, paraparetic), and for excluding mimics (brainstem lesions, myelopathy, cauda equina syndrome)
Peripheral nerve ultrasound may show enlarged cervical nerve roots early in the disease course, with progressive improvement during recovery. Features such as sparing of sensory nerves and transient enlargement of nerve roots or the vagus nerve may help differentiate GBS from acute-onset CIDP with a positive predictive value of >85%. Normalization of nerve size on ultrasound at 6 months provides additional diagnostic support.
Emerging Biomarkers
Serum neurofilament light chain (NfL) has emerged as a promising prognostic biomarker. A 2020 study established cutoff levels at the time of acute illness that correlated with the probability of independent ambulation at 1 year. NfL levels were higher in pure motor variant, Miller Fisher syndrome, and patients with preceding diarrheal illness compared to those with respiratory prodrome and sensorimotor GBS.
Differential Diagnosis
| Presentation | Key Differential Diagnoses |
|---|---|
| Pure motor | Infectious motor neuronopathies (West Nile, enteroviruses, polio, rabies), myopathies, neuromuscular junction disorders (myasthenia gravis, botulism), acute hypokalemic/thyrotoxic periodic paralysis, porphyria, organophosphate toxicity |
| Paraparesis / sensory level | Spinal cord or cauda equina compression, spinal cord infarction, transverse myelitis |
| Asymmetric weakness | Vasculitic neuropathy, multiple mononeuropathies, Lyme disease, diphtheria, leptomeningeal malignancy |
| Cranial neuropathies / ophthalmoplegia | Brainstem stroke, myasthenia gravis, botulism, Wernicke encephalopathy, Lambert-Eaton syndrome |
| Severe diaphragmatic weakness | Myasthenia gravis, high cervical cord lesion, Pompe disease, botulism, hypermagnesemia |
| CSF pleocytosis (>50 cells) | CMV, HIV, Lyme disease, poliovirus, transverse myelitis, leptomeningeal carcinomatosis |
| Other acute polyneuropathies | Critical illness polyneuropathy, toxic neuropathies (arsenic, thallium), tick paralysis, paraneoplastic polyneuropathy |
| Sensory ataxia | Paraneoplastic ganglionopathy, Sjögren syndrome, pyridoxine toxicity, chemotherapy-induced neuropathy |
| Bifacial weakness | Lyme disease, HIV, sarcoidosis, neoplastic meningitis, Melkersson-Rosenthal syndrome |
Treatment
Supportive Care
Supportive care is the cornerstone of GBS management. The following factors should prompt ICU admission: dysautonomia, bulbar dysfunction, severe or rapidly worsening weakness (particularly affecting neck and hip flexors), and evolving respiratory distress.
Respiratory Monitoring — the "20/30/40 Rule"
- The patient is at risk for respiratory failure if:
- Vital capacity <20 mL/kg
- Maximum inspiratory pressure <30 cm H2O
- Maximum expiratory pressure <40 cm H2O
- Monitor every 2–4 hours in the acute setting; a rapid decline (>30% in 24 hours) warrants ICU transfer
- Single-breath counting: inability to count to ≥15 during a single breath predicts subsequent need for mechanical ventilation
- EGRIS >4: A score of more than 4 on the Erasmus GBS Respiratory Insufficiency Score suggests ≥65% risk of respiratory failure within the first week
- Patients who are clinically stable for 2–3 days may have monitoring frequency decreased to every 6–8 hours
Mechanical Ventilation
Required in 10–30% of patients. Intubation should ideally be elective, as emergency intubation can provoke dramatic blood pressure shifts and profound bradycardia in patients with dysautonomia. Important precautions include the use of topical anesthesia, fiberoptic laryngoscopy, short-acting benzodiazepines for sedation, and avoidance of depolarizing neuromuscular blockers (succinylcholine) which can cause fatal hyperkalemia from denervation hypersensitivity. Noninvasive ventilation is usually insufficient and increases the risk of emergency intubation.
Immunotherapy
IVIg and plasma exchange are equally effective when started within 2 and 4 weeks, respectively, of the onset of weakness. Neither therapy stops disease progression or changes the degree of nerve damage — they reduce the time to recovery. Early treatment is preferred to minimize endoneurial inflammation and nerve injury.
| Feature | IVIg | Plasma Exchange |
|---|---|---|
| Dosing | 0.4 g/kg/day × 5 days, or 1 g/kg/day × 2 days | 200–250 mL plasma/kg over 5 sessions in 10 days |
| General preference | Preferred due to better tolerability and ease of administration | Consider based on availability, cost, and patient factors |
| Adverse effects | Transfusion reactions, headache/aseptic meningitis, rash, hyperosmolar kidney injury (sucrose-containing products), thromboembolism, IgA deficiency-related anaphylaxis (rare) | Hypotension, sepsis, transfusion reactions, thrombocytopenia, impaired clotting, hypocalcemia, IV access complications |
| Special considerations | 2-day course in children associated with more treatment-related fluctuations than 5-day course | 2 exchanges for mildly affected patients; ≥4 exchanges for severely affected; higher discontinuation rate than IVIg |
Treatment of Non-Responders
Up to 40% of patients report no clinical improvement after reaching a plateau (~4 weeks) following initiation of immunotherapy. Neither combination therapy (plasma exchange followed by IVIg, or vice versa) nor a second course of IVIg provides additional benefit. Importantly, lack of early improvement may not indicate treatment inefficacy, as progression could have been worse without therapy. Early supportive interventions are recommended, including percutaneous endoscopic gastrostomy if needed, tracheostomy (after at least 2 weeks of mechanical ventilation if pulmonary function does not improve sufficiently), and discharge to rehabilitation.
Treatment by Subtype
- AMAN: Limited evidence suggests that plasma exchange may be more effective than IVIg; once axonal degeneration is confirmed and other causes excluded, early supportive interventions and multidisciplinary rehabilitation are recommended rather than combining or repeating immunotherapies
- Miller Fisher syndrome: Most patients experience a mild, self-limited course that resolves completely in 6 months without treatment; close monitoring and immunotherapy may be warranted if progressive spread to limb, cranial, or respiratory muscles occurs
Corticosteroids
Corticosteroids Are NOT Effective in GBS
- Eight randomized controlled trials have revealed no significant benefit of corticosteroids in GBS
- Treatment with oral corticosteroids has a detrimental impact on clinical outcomes
- This finding is notable because corticosteroids are effective in CIDP, underscoring the distinct pathophysiology of the two conditions
Case Vignette
Case: Rapidly Progressive AMAN
A 32-year-old man without significant medical history presented with 2 days of diffuse limb weakness. Without any preceding illness, he awoke with neck pain and extremity weakness. On examination: severe symmetric proximal (MRC 3/5) and distal (MRC 2/5) weakness with global areflexia; sensation intact. Within hours, he progressed to quadriplegia. Initial CSF was normal (protein 28 mg/dL). IVIg was initiated, but he required intubation by day 2.
Electrodiagnostic testing on day 14 showed absent CMAPs in median, ulnar, peroneal, and tibial nerves with normal SNAPs, confirming AMAN. Repeat LP on day 15 revealed elevated protein (63 mg/dL). Serum C. jejuni IgG titer was elevated (1:1280; normal <1:320) despite no preceding symptomatic illness, illustrating subclinical infection.
Key lessons: (1) Weakness can progress alarmingly fast, requiring intubation within days. (2) Subclinical infection is present in 28% of GBS patients. (3) Once extensive axonal degeneration is documented, supportive care and rehabilitation are preferred over combining or repeating immunotherapies.
Prognosis
Validated Prognostic Models
| Tool | Variables | Prediction | Scoring |
|---|---|---|---|
| EGRIS | Time from weakness onset to hospitalization; facial/bulbar weakness at admission; MRC sum score at admission | Risk of respiratory failure within first week of hospitalization | 0–7; score >4 = ≥65% risk of respiratory failure |
| mEGOS | Patient age; preceding diarrhea (yes/no); MRC sum score at admission or 1 week post-admission | Probability of independent walking at 1, 3, and 6 months | 0–12; higher scores indicate higher risk of poor outcome |
Both tools are available online at gbstools.erasmusmc.nl.
Long-Term Outcomes
- Favorable outcomes: Approximately 80% of patients walk independently and more than half recover fully after 1 year
- Axonal loss: Persistently low-amplitude CMAPs are a poor prognostic factor; recovery may continue beyond 1 year and may remain incomplete
- Residual deficits: Weakness, paresthesia, fatigue, and pain can persist beyond 1 year, impacting daily activities and quality of life; 32% of patients had to change their work because of GBS
Mortality
- Overall mortality: 3–7%
- Ventilator-dependent patients: ~20% mortality
- Low-resource settings: mortality among ventilated patients reaches 41%, linked to inadequate ICU facilities, subspecialty care, and absence of immunomodulatory treatments
- Predictors of death: Advanced age, severe disease, comorbidities, pulmonary and cardiac complications, mechanical ventilation, systemic infection
- Common causes of death: Acute respiratory distress syndrome, infections, pulmonary emboli, sudden cardiac arrest — these can occur during both the acute and recovery periods
- Sex is not a reliable prognostic indicator despite male predominance
Prognosis in Special Situations
- COVID-19-associated GBS: No appreciable difference in clinical manifestations compared to typical GBS
- Zika-associated GBS: Higher rates of bulbar/facial weakness, dyspnea, need for mechanical ventilation, and residual facial and bulbar deficits at 6 months
References
- Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866-2877.
- Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214-1228.
- Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998;51(4):1110-1115.
- Koike H, Chiba A, Katsuno M. Emerging infection, vaccination, and Guillain-Barré syndrome: a review. Neurol Ther. 2021;10(2):523-537.
- Leonhard SE, van der Eijk AA, Andersen H, et al. An international perspective on preceding infections in Guillain-Barré syndrome: the IGOS-1000 cohort. Neurology. 2022;99(12):e1299-e1313.
- Keddie S, Pakpoor J, Mousele C, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2021;144(2):682-693.
- Hanson KE, Goddard K, Lewis N, et al. Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the Vaccine Safety Datalink. JAMA Netw Open. 2022;5(4):e228879.
- Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(Suppl 1):S21-S24.
- Fokke C, van den Berg B, Drenthen J, et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(Pt 1):33-43.
- Chakraborty T, Kramer CL, Wijdicks EFM, Rabinstein AA. Dysautonomia in Guillain-Barré syndrome: prevalence, clinical spectrum, and outcomes. Neurocrit Care. 2020;32(1):113-120.
- Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol. 2013;12(12):1180-1188.
- Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003;126(Pt 10):2279-2290.
- Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-727.
- Kieseier BC, Mathey EK, Sommer C, Hartung HP. Immune-mediated neuropathies. Nat Rev Dis Primers. 2018;4(1):31.
- Al-Hakem H, Doets AY, Stino AM, et al. CSF findings in relation to clinical characteristics, subtype, and disease course in patients with Guillain-Barré syndrome. Neurology. 2023;100(23):e2386-e2397.
- Uncini A, Kuwabara S. The electrodiagnosis of Guillain-Barré syndrome subtypes: where do we stand? Clin Neurophysiol. 2018;129(12):2586-2593.
- Derksen A, Ritter C, Athar P, et al. Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics. Muscle Nerve. 2014;50(5):780-784.
- Yikilmaz A, Doganay S, Gumus H, et al. Magnetic resonance imaging of childhood Guillain-Barré syndrome. Childs Nerv Syst. 2010;26(8):1103-1108.
- Grimm A, Oertl H, Auffenberg E, et al. Differentiation between Guillain-Barré syndrome and acute-onset chronic inflammatory demyelinating polyradiculoneuritis. Neurotherapeutics. 2019;16(3):838-847.
- Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010;67(6):781-787.
- Doets AY, Walgaard C, Lingsma HF, et al. International validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score. Ann Neurol. 2022;91(4):521-531.
- Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2017;2(2):CD001798.
- Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;(9):CD002063.
- Verboon C, van Doorn PA, Jacobs BC. Treatment dilemmas in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2017;88(4):346-352.
- Walgaard C, Jacobs BC, Lingsma HF, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(4):275-283.
- Kalita J, Misra UK, Chaudhary SK, et al. Outcome of Guillain-Barré syndrome following intravenous immunoglobulin compared to natural course. Eur J Neurol. 2022;29(10):3071-3080.
- Hughes RAC, Swan AV, Raphael JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130(Pt 9):2245-2257.
- Doets AY, Lingsma HF, Walgaard C, et al. Predicting outcome in Guillain-Barré syndrome: international validation of the Modified Erasmus GBS Outcome Score. Neurology. 2022;98(5):e518-e532.
- van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC. Mortality in Guillain-Barré syndrome. Neurology. 2013;80(18):1650-1654.
- Bernsen RAJAM, de Jager AEJ, van der Meché FGA, Suurmeijer TPBM. How Guillain-Barré patients experience their functioning after 1 year. Acta Neurol Scand. 2005;112(1):51-56.
- Islam Z, Papri N, Ara G, et al. Risk factors for respiratory failure in Guillain-Barré syndrome in Bangladesh: a prospective study. Ann Clin Transl Neurol. 2019;6(2):324-332.
- Martin-Aguilar L, Camps-Renom P, Lleixa C, et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. J Neurol Neurosurg Psychiatry. 2020.